Efficacia della mesalazina (5-ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari

Translated title of the contribution: Efficacy of low dose mesalazine (5-ASA) in the treatment of acute inflammation and prevention of complications in patients with symptomatic diverticular disease. Preliminary results

E. Trespi, P. Panizza, C. Colla, G. Bottani, P. De Vecchi, C. Matti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Materials and methods. To assess the efficacy of mesalazine in treating acute diverticulitis and preventing diverticular disease (DD) complication. 166 patients with symptomatic DD were randomly assigned to receive mesalazine Pentacol® (400 mg b.i.d., orally; M group) or no additional treatment (controls; C group). Results. After a 12 months follow-up, 26 patients experienced a symptomatic relapse (8% M vs 27% C, p = 0.003), with a higher rate in C group for the patients with a history of previous diverticulitis (p = 0.006) and independently of the diverticular site (sigmoid p = 0.041; colon and sigmoid p = 0.044). Minor diverticular haemorrhages were less frequent in M group (p = 0.016), with a significant difference only for the patients with sigmoid diverticula (p = 0.023); abdominal pain persisted for a shorter time in the treated group (p = 0.0015). Conclusions. No significant difference was found between the two groups for the incidence of DD major complications.

Original languageItalian
Pages (from-to)157-162
Number of pages6
JournalMinerva Gastroenterologica e Dietologica
Volume43
Issue number3
Publication statusPublished - 1997

Fingerprint

Mesalamine
Sigmoid Colon
Inflammation
Diverticulitis
Diverticulum
Therapeutics
Abdominal Pain
Hemorrhage
Recurrence
Control Groups
Incidence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{b2985e5e6e3644d7bb42849a7596709e,
title = "Efficacia della mesalazina (5-ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari",
abstract = "Materials and methods. To assess the efficacy of mesalazine in treating acute diverticulitis and preventing diverticular disease (DD) complication. 166 patients with symptomatic DD were randomly assigned to receive mesalazine Pentacol{\circledR} (400 mg b.i.d., orally; M group) or no additional treatment (controls; C group). Results. After a 12 months follow-up, 26 patients experienced a symptomatic relapse (8{\%} M vs 27{\%} C, p = 0.003), with a higher rate in C group for the patients with a history of previous diverticulitis (p = 0.006) and independently of the diverticular site (sigmoid p = 0.041; colon and sigmoid p = 0.044). Minor diverticular haemorrhages were less frequent in M group (p = 0.016), with a significant difference only for the patients with sigmoid diverticula (p = 0.023); abdominal pain persisted for a shorter time in the treated group (p = 0.0015). Conclusions. No significant difference was found between the two groups for the incidence of DD major complications.",
keywords = "aminosalicylic acids, therapeutic use, anti-inflammatory agents, non steroidal, therapeutic use, diverticulitis, colonic drug therapy",
author = "E. Trespi and P. Panizza and C. Colla and G. Bottani and {De Vecchi}, P. and C. Matti",
year = "1997",
language = "Italian",
volume = "43",
pages = "157--162",
journal = "Minerva Gastroenterologica",
issn = "0026-4776",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Efficacia della mesalazina (5-ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari

AU - Trespi, E.

AU - Panizza, P.

AU - Colla, C.

AU - Bottani, G.

AU - De Vecchi, P.

AU - Matti, C.

PY - 1997

Y1 - 1997

N2 - Materials and methods. To assess the efficacy of mesalazine in treating acute diverticulitis and preventing diverticular disease (DD) complication. 166 patients with symptomatic DD were randomly assigned to receive mesalazine Pentacol® (400 mg b.i.d., orally; M group) or no additional treatment (controls; C group). Results. After a 12 months follow-up, 26 patients experienced a symptomatic relapse (8% M vs 27% C, p = 0.003), with a higher rate in C group for the patients with a history of previous diverticulitis (p = 0.006) and independently of the diverticular site (sigmoid p = 0.041; colon and sigmoid p = 0.044). Minor diverticular haemorrhages were less frequent in M group (p = 0.016), with a significant difference only for the patients with sigmoid diverticula (p = 0.023); abdominal pain persisted for a shorter time in the treated group (p = 0.0015). Conclusions. No significant difference was found between the two groups for the incidence of DD major complications.

AB - Materials and methods. To assess the efficacy of mesalazine in treating acute diverticulitis and preventing diverticular disease (DD) complication. 166 patients with symptomatic DD were randomly assigned to receive mesalazine Pentacol® (400 mg b.i.d., orally; M group) or no additional treatment (controls; C group). Results. After a 12 months follow-up, 26 patients experienced a symptomatic relapse (8% M vs 27% C, p = 0.003), with a higher rate in C group for the patients with a history of previous diverticulitis (p = 0.006) and independently of the diverticular site (sigmoid p = 0.041; colon and sigmoid p = 0.044). Minor diverticular haemorrhages were less frequent in M group (p = 0.016), with a significant difference only for the patients with sigmoid diverticula (p = 0.023); abdominal pain persisted for a shorter time in the treated group (p = 0.0015). Conclusions. No significant difference was found between the two groups for the incidence of DD major complications.

KW - aminosalicylic acids, therapeutic use

KW - anti-inflammatory agents, non steroidal, therapeutic use

KW - diverticulitis, colonic drug therapy

UR - http://www.scopus.com/inward/record.url?scp=84873490966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873490966&partnerID=8YFLogxK

M3 - Articolo

C2 - 16501486

AN - SCOPUS:84873490966

VL - 43

SP - 157

EP - 162

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 0026-4776

IS - 3

ER -